Cargando…

Economic burden of varicella in children 1–12 Years of age in Hungary, 2011–2015

BACKGROUND: Although live-attenuated varicella-zoster virus (VZV) vaccines have been proven to be safe and effective in preventing varicella and real-word evidence shows routine childhood immunization programs are effective in dramatically reducing varicella associated morbidity and mortality, varic...

Descripción completa

Detalles Bibliográficos
Autores principales: Meszner, Z., Molnar, Z., Rampakakis, E., Yang, H. K., Kuter, B. J., Wolfson, Lara J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513371/
https://www.ncbi.nlm.nih.gov/pubmed/28705150
http://dx.doi.org/10.1186/s12879-017-2575-6
_version_ 1783250647089414144
author Meszner, Z.
Molnar, Z.
Rampakakis, E.
Yang, H. K.
Kuter, B. J.
Wolfson, Lara J.
author_facet Meszner, Z.
Molnar, Z.
Rampakakis, E.
Yang, H. K.
Kuter, B. J.
Wolfson, Lara J.
author_sort Meszner, Z.
collection PubMed
description BACKGROUND: Although live-attenuated varicella-zoster virus (VZV) vaccines have been proven to be safe and effective in preventing varicella and real-word evidence shows routine childhood immunization programs are effective in dramatically reducing varicella associated morbidity and mortality, varicella vaccine is not included in the National Immunization Program (NIP) in Hungary. The purpose of this study was to evaluate the clinical and economic burden associated with varicella in Hungary. METHODS: This was a multicenter, retrospective, chart review study of patients aged 1–12 years with a primary varicella diagnosis between 2011 and 2015. Healthcare resource utilization (HCRU) associated with varicella, unit costs, and work loss were used to estimate direct and indirect costs. All costs are presented in 2015 HUF / Euros (€). RESULTS: 156 children with varicella were included (75 outpatients, 81 inpatients), with a mean age of 4.4 (SD: 2.0) and 3.7 (SD: 2.1) years, respectively. One or more complications were reported by 12.0% of outpatients and 92.6% of inpatients, the most common being dehydration, skin and soft tissue infections, pneumonia, keratoconjunctivitis, and cerebellitis. HCRU estimates included use of over-the-counter (OTC) medications (96.0% outpatients, 53.1% inpatients), prescription medications (9.3% outpatients, 70.4% inpatients), tests/procedures (4.0% outpatients, 97.5% inpatients), and consultation with allied health professionals (2.7% outpatients, 30.9% inpatients). The average duration of hospital stay (inpatients) was 3.6 (95% CI: 3.2, 4.1) days. The total combined direct and indirect cost per varicella case was 228,146.7 Hungarian Forint (HUF)/€ 736.0 for inpatients and 49,790.6 HUF/€ 106.6 for outpatients. The overall annual cost of varicella in Hungary for children aged <15 years in 2015 was estimated at 1,903,332,524.3 HUF/ € 6,139,980.4. CONCLUSION: Varicella is associated with substantial clinical burden in Hungary, resulting in the utilization of a significant amount of healthcare resources. These results support the need for routine vaccination of all healthy children to reduce the varicella-associated disease burden.
format Online
Article
Text
id pubmed-5513371
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55133712017-07-19 Economic burden of varicella in children 1–12 Years of age in Hungary, 2011–2015 Meszner, Z. Molnar, Z. Rampakakis, E. Yang, H. K. Kuter, B. J. Wolfson, Lara J. BMC Infect Dis Research Article BACKGROUND: Although live-attenuated varicella-zoster virus (VZV) vaccines have been proven to be safe and effective in preventing varicella and real-word evidence shows routine childhood immunization programs are effective in dramatically reducing varicella associated morbidity and mortality, varicella vaccine is not included in the National Immunization Program (NIP) in Hungary. The purpose of this study was to evaluate the clinical and economic burden associated with varicella in Hungary. METHODS: This was a multicenter, retrospective, chart review study of patients aged 1–12 years with a primary varicella diagnosis between 2011 and 2015. Healthcare resource utilization (HCRU) associated with varicella, unit costs, and work loss were used to estimate direct and indirect costs. All costs are presented in 2015 HUF / Euros (€). RESULTS: 156 children with varicella were included (75 outpatients, 81 inpatients), with a mean age of 4.4 (SD: 2.0) and 3.7 (SD: 2.1) years, respectively. One or more complications were reported by 12.0% of outpatients and 92.6% of inpatients, the most common being dehydration, skin and soft tissue infections, pneumonia, keratoconjunctivitis, and cerebellitis. HCRU estimates included use of over-the-counter (OTC) medications (96.0% outpatients, 53.1% inpatients), prescription medications (9.3% outpatients, 70.4% inpatients), tests/procedures (4.0% outpatients, 97.5% inpatients), and consultation with allied health professionals (2.7% outpatients, 30.9% inpatients). The average duration of hospital stay (inpatients) was 3.6 (95% CI: 3.2, 4.1) days. The total combined direct and indirect cost per varicella case was 228,146.7 Hungarian Forint (HUF)/€ 736.0 for inpatients and 49,790.6 HUF/€ 106.6 for outpatients. The overall annual cost of varicella in Hungary for children aged <15 years in 2015 was estimated at 1,903,332,524.3 HUF/ € 6,139,980.4. CONCLUSION: Varicella is associated with substantial clinical burden in Hungary, resulting in the utilization of a significant amount of healthcare resources. These results support the need for routine vaccination of all healthy children to reduce the varicella-associated disease burden. BioMed Central 2017-07-14 /pmc/articles/PMC5513371/ /pubmed/28705150 http://dx.doi.org/10.1186/s12879-017-2575-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Meszner, Z.
Molnar, Z.
Rampakakis, E.
Yang, H. K.
Kuter, B. J.
Wolfson, Lara J.
Economic burden of varicella in children 1–12 Years of age in Hungary, 2011–2015
title Economic burden of varicella in children 1–12 Years of age in Hungary, 2011–2015
title_full Economic burden of varicella in children 1–12 Years of age in Hungary, 2011–2015
title_fullStr Economic burden of varicella in children 1–12 Years of age in Hungary, 2011–2015
title_full_unstemmed Economic burden of varicella in children 1–12 Years of age in Hungary, 2011–2015
title_short Economic burden of varicella in children 1–12 Years of age in Hungary, 2011–2015
title_sort economic burden of varicella in children 1–12 years of age in hungary, 2011–2015
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513371/
https://www.ncbi.nlm.nih.gov/pubmed/28705150
http://dx.doi.org/10.1186/s12879-017-2575-6
work_keys_str_mv AT mesznerz economicburdenofvaricellainchildren112yearsofageinhungary20112015
AT molnarz economicburdenofvaricellainchildren112yearsofageinhungary20112015
AT rampakakise economicburdenofvaricellainchildren112yearsofageinhungary20112015
AT yanghk economicburdenofvaricellainchildren112yearsofageinhungary20112015
AT kuterbj economicburdenofvaricellainchildren112yearsofageinhungary20112015
AT wolfsonlaraj economicburdenofvaricellainchildren112yearsofageinhungary20112015